Sunobinop

DB18955InvestigationalSmall molecule

Sunobinop is under investigation in clinical trial NCT04035200 (Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation).

Mechanism: Pharmacologically active on Nociceptin receptor
Curator reviewed
Formula / weight: C₂₆H₃₃N₃O₃ · 435.568 g/mol (avg)
Also known as: 2-quinoxalinecarboxylic acid, 4-((3-endo)-9-(3-exo)-bicyclo(3.3.1)non-3-yl-9-azabicyclo(3.3.1)non-3-yl)-3,4-dihydro-3-oxo- · 4-((1r,1'r,3r,3'r,5s,5's)-9'-aza(3,9'- bi(bicyclo(3.3.1)nonan))-3'-yl)-3-oxo-3,4- dihydroquinoxaline-2-carboxylic acid
Code names: IMB-115 · RSC117957 · V-117957

Resolves to

Compound

UNIII1X86U5474CAS1126793-40-5

Structure

InChIKeyCOTYYZPYDJKKIS-VDRZXAFZSA-NSMILES[H]C1(C[C@H]2CCC[C@@H](C2)C1)N1[C@H]2CCC[C@@H]1C[C@@H](C2)N1C(=O)C(=NC2=CC=CC=C12)C(O)=O

Targets

P41146OPRL1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sunobinop, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account